抑制FOXO1产生强大的非激活的CAR T细胞来对抗固体瘤
Maude Marchais1,2, Luca Simula2, Mélanie Phayanouvong3
1CNRS UMR9196, Physiologie et Pathologie Moléculaires des Rétrovirus Endogènes et Infectieux, Gustave Roussy, Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
Cancer immunology research
|August 30, 2023
概括
研究人员开发了一种新方法,通过抑制FOXO1.1,在没有活体预激活的情况下创建嵌合式抗原受体 (CAR) T细胞. 这种新型的CAR T细胞疗法增强了抗瘤功能,并显示出对固体瘤的疗效有所改善.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- 化学抗原受体 (CAR) T细胞疗法对B细胞恶性瘤有希望,但面临着制造方面的挑战.
- 虽然ex vivo激活对于CAR T细胞扩张是必要的,但可以降低它们的抗瘤潜力.
- 改善CAR T细胞特性对于提高治疗疗效至关重要,特别是在固体瘤中.
研究的目的:
- 开发一个协议,在没有外活体预激活的情况下生成CAR-T细胞.
- 研究抑制转录因子FOXO1对T细胞功能和CAR表达的影响.
- 评估这些修饰的CAR T细胞 (CAR TAS) 对固体瘤的治疗潜力.
主要方法:
- 在初级T细胞中抑制转录因子FOXO1,以产生T细胞激活和生存 (TAS) 细胞.
- 在没有活体预激活的情况下,TAS细胞的lentiviral转导产生CAR TAS细胞.
- 在固体瘤模型中评估CAR TAS细胞表型,功能 (增殖,细胞毒性,迁移) 和体内疗效.
主要成果:
- 抑制FOXO1使得T细胞对lentiviral感染具有宽容性,使CAR表达成为可能.
- 卡塔斯细胞表现出干细胞记忆表型,增加了大酶B和TNFα的产生.
- 与经典的CAR T细胞相比,CAR TAS细胞表现出增强的增殖,细胞毒性和迁移能力.
- 在体内研究证实了CAR TAS细胞对固体瘤生长的优越控制.
- 该方案的临床可行性使用患者衍生细胞得到验证.
结论:
- 抑制FOXO1是一种可行的策略,可以在没有活体预激活的情况下产生强大的CAR T细胞.
- CAR TAS细胞具有增强的抗瘤功能,为改善CAR T细胞疗法提供了一个有前途的方法,特别是在固体瘤中.
- 该协议可用于临床应用,为基于细胞的增强癌症免疫疗法铺平了道路.
相关概念视频
Tumor Immunotherapy
555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
T Cell Activation and Clonal Selection
804
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
804
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response
963
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
963


